Survival outcomes and response in patients treated with VEN compared withPBO. (A) Kaplan-Meier OS curves of all patients. Number of patients at risk for each time is shown below and separated by treatment arms. (B) Kaplan-Meier duration of response curves in patients treated with VEN + LDAC. Number of patients at risk for each time is shown below and separated by response. (C) Kaplan-Meier OS by prior HMA treatment curves in patients treated with VEN + LDAC. Number of patients at risk for each time is shown below and separated by prior HMA treatment. (D) Kaplan-Meier OS by remission status curves in patients treated with VEN + LDAC. Number of patients at risk for each time is shown below and separated by response. (E) Kaplan-Meier OS by AML type curves in patients treated with VEN + LDAC. Number of patients at risk for each time is shown below and separated by AML type. (F) Kaplan-Meier OS by mutational status curves in patients treated with VEN + LDAC. Number of patients at risk for each time is shown below and separated by mutational status. AML, acute myeloid leukemia; CR, complete remission; CRi, complete remission with incomplete blood count recovery; DOR, duration of remission; HMA, hypomethylating agent; LDAC, low dose cytarabine; PBO, placebo; VEN, venetoclax.